Help employers find you! Check out all the
CALGARY, July 23, 2014 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the
"Company") today announced that it has appointed Julie Cherrington PhD
to act as the President and Chief Executive Officer of Zenith
Epigenetics Corp. Julie has an extensive background leading companies
focused on the discovery and development of novel cancer therapeutics
and is well-versed in the challenges of developing drugs and advancing
them into the clinic and through to commercialization. Her
accomplished employment record includes past notable positions such as
CEO of Pathway Therapeutics Inc., President of Phenomix Corporation,
Vice President, Preclinical Research and Exploratory Development
SUGEN/Pharmacia/Pfizer, and Director, Virology at Gilead Sciences.
Notably, Julie was a key contributor to the successful development of
multiple FDA approved products including anti-virals (Vistide,
Viread, Hepsera) and anti-cancer agents (SUTENT, Palladia).
Dr. Cherrington remarked, "I am very excited to be joining Zenith
Epigenetics at such an important time in the growth of the company. We
are set to embark on the first clinical application of the strong
scientific foundation of Zenith".
Donald J. McCaffrey, founding CEO, will assume the title of Chairman and
Dr. Peter Johann will act as Lead Director. "I am very proud of the
progress made by Zenith in the past year and am delighted to hand over
the reins to Julie to lead the company, advancing our programs and
creating value for Zenith. I look forward to working with Julie and to
continue supporting the company in my role as Chairman of the Board of
Directors", commented Don McCaffrey.
Zenith Epigenetics Corp. is a clinical stage biotechnology company
focused on the discovery and development of novel therapeutics by
applying its proprietary epigenetics platform. Zenith's bromodomain
(BET) inhibitors are being advanced in several oncology indications and
have the potential to impact multiple additional diseases as well.
SOURCE Zenith Epigenetics Corp.